Brexpiprazole
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317111

CAS#: 913611-97-9

Description: Brexpiprazole, also known as OPC-34712, is a novel D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM) approved for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD). Brexpiprazole was approved on 7/10/2015 to treat schizophrenia and as an add on to an antidepressant to treat major depressive disorder


Chemical Structure

img
Brexpiprazole
CAS# 913611-97-9

Theoretical Analysis

MedKoo Cat#: 317111
Name: Brexpiprazole
CAS#: 913611-97-9
Chemical Formula: C25H27N3O2S
Exact Mass: 433.1824
Molecular Weight: 433.57
Elemental Analysis: C, 69.26; H, 6.28; N, 9.69; O, 7.38; S, 7.39

Price and Availability

Size Price Availability Quantity
200.0mg USD 150.0 Same day
500.0mg USD 350.0 Same day
1.0g USD 650.0 Same day
2.0g USD 1050.0 Same day
5.0g USD 1950.0 Same day
10.0g USD 2950.0 Same day
20.0g USD 3950.0 2 Weeks
50.0g USD 6950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: OPC-34712; OPC 34712; OPC34712; Brexpiprazole; brand name Rexulti.

IUPAC/Chemical Name: 7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one

InChi Key: ZKIAIYBUSXZPLP-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)

SMILES Code: O=C1NC2=C(C=CC(OCCCCN3CCN(C4=C5C=CSC5=CC=C4)CC3)=C2)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 433.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jackowiak EM, Chou KL. Severe parkinsonism caused by brexpiprazole: A case report. Parkinsonism Relat Disord. 2019 Nov 13;69:138-139. doi: 10.1016/j.parkreldis.2019.11.013. [Epub ahead of print] PubMed PMID: 31756572.

2: Yoshimura Y, Shimizu H, Yamashita R, Washida K, Takeda T, Aoki S. Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol. 2019 Nov 15. doi: 10.1097/YIC.0000000000000296. [Epub ahead of print] PubMed PMID: 31743231.

3: Suzuki M, Niidome K, Maeda K, Kikuchi T, Usami T, Futamura T. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI(®) Tablets 1 mg, 2 mg)]. Nihon Yakurigaku Zasshi. 2019;154(5):275-287. doi: 10.1254/fpj.154.275. Japanese. PubMed PMID: 31735758.

4: Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade RD, Cummings JL. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Am J Geriatr Psychiatry. 2019 Oct 1. pii: S1064-7481(19)30521-4. doi: 10.1016/j.jagp.2019.09.009. [Epub ahead of print] PubMed PMID: 31708380.

5: Sanagawa A, Shiraishi N, Sekiguchi F, Akechi T, Kimura K. Successful Use of Brexpiprazole for Parkinson's Disease Psychosis Without Adverse Effects: A Case Report. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):685-687. doi: 10.1097/JCP.0000000000001127. PubMed PMID: 31688389.

6: Okada T, Kumakura J, Yasuda M, Suda S. Treatment-resistant schizophrenia successfully maintained with brexpiprazole following abrupt withdrawal of clozapine due to neutropenia. Asian J Psychiatr. 2019 Oct 18;47:101836. doi: 10.1016/j.ajp.2019.10.016. [Epub ahead of print] PubMed PMID: 31677398.

7: Citrome L, Ouyang J, Shi L, Meehan SR, Baker RA, Weiss C. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):597-603. doi: 10.1097/JCP.0000000000001113. PubMed PMID: 31652166.

8: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548464/ PubMed PMID: 31643783.

9: Newcomer JW, Eriksson H, Zhang P, Meehan SR, Weiss C. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies. J Clin Psychiatry. 2019 Oct 1;80(6). pii: 18m12680. doi: 10.4088/JCP.18m12680. PubMed PMID: 31577867.

10: Chen B, Zhang XD, Wen J, Zhang B, Chen D, Wang S, Cai JP, Hu GX. Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism. Chem Res Toxicol. 2019 Oct 17. doi: 10.1021/acs.chemrestox.9b00186. [Epub ahead of print] PubMed PMID: 31560202.

11: Sanomachi T, Suzuki S, Togashi K, Seino S, Yoshioka T, Kitanaka C, Okada M, Yamamoto M. Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. Anticancer Res. 2019 Sep;39(9):4817-4828. doi: 10.21873/anticanres.13667. PubMed PMID: 31519584.

12: Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H, Kurahashi N, Kikuchi T, Futamura T. Brexpiprazole has a low risk of dopamine D(2) receptor sensitization and inhibits rebound phenomena related to D(2) and serotonin 5-HT(2A) receptors in rats. Neuropsychopharmacol Rep. 2019 Sep 5. doi: 10.1002/npr2.12076. [Epub ahead of print] PubMed PMID: 31487433.

13: Fornaro M, Fusco A, Anastasia A, Cattaneo CI, De Berardis D. Brexpiprazole for treatment-resistant major depressive disorder. Expert Opin Pharmacother. 2019 Nov;20(16):1925-1933. doi: 10.1080/14656566.2019.1654457. Epub 2019 Aug 20. PubMed PMID: 31431092.

14: Cha DS, Luo X, Ahmed J, Becirovic L, Cha RH, McIntyre RS. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder. Expert Rev Neurother. 2019 Sep;19(9):777-783. doi: 10.1080/14737175.2019.1653759. Epub 2019 Aug 14. PubMed PMID: 31389279.

15: Davis JM. Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E., Kaspar, S., Pallanti S., Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):1061-1062. doi: 10.1016/j.euroneuro.2019.07.001. Epub 2019 Jul 29. PubMed PMID: 31371104.

16: Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2019 Nov 1;22(11):698-709. doi: 10.1093/ijnp/pyz040. PubMed PMID: 31350882; PubMed Central PMCID: PMC6872963.

17: Thase ME, Zhang P, Weiss C, Meehan SR, Hobart M. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opin Pharmacother. 2019 Oct;20(15):1907-1916. doi: 10.1080/14656566.2019.1638913. Epub 2019 Jul 10. Review. PubMed PMID: 31290344.

18: Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M. Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. Cancers (Basel). 2019 Jul 5;11(7). pii: E947. doi: 10.3390/cancers11070947. PubMed PMID: 31284441; PubMed Central PMCID: PMC6679129.

19: Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. doi: 10.1016/j.euroneuro.2019.06.008. Epub 2019 Jun 27. Review. PubMed PMID: 31255396.

20: Suzuki S, Yamamoto M, Togashi K, Sanomachi T, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M. In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile. Oncotarget. 2019 May 28;10(37):3547-3558. doi: 10.18632/oncotarget.26949. eCollection 2019 May 28. PubMed PMID: 31191825; PubMed Central PMCID: PMC6544401.